[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IN2014DN10680A - - Google Patents

Download PDF

Info

Publication number
IN2014DN10680A
IN2014DN10680A IN10680DEN2014A IN2014DN10680A IN 2014DN10680 A IN2014DN10680 A IN 2014DN10680A IN 10680DEN2014 A IN10680DEN2014 A IN 10680DEN2014A IN 2014DN10680 A IN2014DN10680 A IN 2014DN10680A
Authority
IN
India
Prior art keywords
polymorphic forms
crystalline polymorphic
respiratory
disease
mdt
Prior art date
Application number
Inventor
Robert O Cook
Eugene R Reynolds
Boris Shekunov
Siead I Zegar
Original Assignee
Microdose Therapeutx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microdose Therapeutx Inc filed Critical Microdose Therapeutx Inc
Publication of IN2014DN10680A publication Critical patent/IN2014DN10680A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides novel crystalline polymorphic forms of MDT 637 in particular crystalline polymorphic forms with physicochemical properties specifically suited for drug production amorphous formation composite form and methods of preparation thereof. The novel polymorphs described herein are useful for the treatment of respiratory disease such as disease caused by respiratory syncytial virus.
IN10680DEN2014 2012-06-29 2013-06-28 IN2014DN10680A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666258P 2012-06-29 2012-06-29
PCT/US2013/048723 WO2014005098A2 (en) 2012-06-29 2013-06-28 Compositions and methods for treating or preventing pneumovirus infection and associated diseases

Publications (1)

Publication Number Publication Date
IN2014DN10680A true IN2014DN10680A (en) 2015-08-28

Family

ID=49778754

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10680DEN2014 IN2014DN10680A (en) 2012-06-29 2013-06-28

Country Status (17)

Country Link
US (2) US9040569B2 (en)
EP (1) EP2867216A4 (en)
JP (1) JP2015524391A (en)
KR (1) KR20150037946A (en)
CN (1) CN104507918A (en)
AU (1) AU2013282286A1 (en)
BR (1) BR112014032290A2 (en)
CA (1) CA2877941A1 (en)
EA (1) EA201590124A1 (en)
HK (2) HK1203956A1 (en)
IL (1) IL236476A0 (en)
IN (1) IN2014DN10680A (en)
MX (1) MX2014015340A (en)
NZ (1) NZ628880A (en)
TW (1) TWI516283B (en)
WO (1) WO2014005098A2 (en)
ZA (1) ZA201409073B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9040569B2 (en) 2012-06-29 2015-05-26 Microdose Therapeutx Compositions and methods for treating or preventing pneumovirus infection and associated diseases
WO2016096143A1 (en) * 2014-12-18 2016-06-23 Metriopharm Ag Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said form
MX2018006575A (en) * 2015-11-30 2018-12-06 Novus Therapeutics Inc Compositions and methods for otologic prophylaxis and treatment.
WO2018071443A1 (en) 2016-10-11 2018-04-19 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
AU2019339401B9 (en) * 2018-09-14 2022-11-03 Pharmosa Biopharm Inc. Pharmaceutical composition for controlled release of weak acid drugs and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495580B1 (en) * 1998-01-29 2002-12-17 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
JP2002501894A (en) * 1998-01-29 2002-01-22 バイロファーマ・インコーポレイテッド Compounds, compositions and methods for treating or preventing pneumovirus infection and related diseases
WO2002059132A1 (en) 2001-01-26 2002-08-01 Viropharma Incorporated Intermediate compounds useful for making antiviral compounds
CA2495245A1 (en) 2002-08-09 2004-02-19 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
CA2495266A1 (en) 2002-08-09 2004-02-19 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
US9040569B2 (en) 2012-06-29 2015-05-26 Microdose Therapeutx Compositions and methods for treating or preventing pneumovirus infection and associated diseases

Also Published As

Publication number Publication date
CN104507918A (en) 2015-04-08
WO2014005098A2 (en) 2014-01-03
US20150209328A1 (en) 2015-07-30
EP2867216A2 (en) 2015-05-06
MX2014015340A (en) 2015-03-05
CA2877941A1 (en) 2014-01-03
BR112014032290A2 (en) 2017-06-27
US9040569B2 (en) 2015-05-26
KR20150037946A (en) 2015-04-08
US20140005239A1 (en) 2014-01-02
JP2015524391A (en) 2015-08-24
AU2013282286A1 (en) 2015-01-22
EP2867216A4 (en) 2015-12-09
EA201590124A1 (en) 2015-06-30
IL236476A0 (en) 2015-02-26
HK1210163A1 (en) 2016-04-15
TWI516283B (en) 2016-01-11
ZA201409073B (en) 2016-08-31
TW201416093A (en) 2014-05-01
US9504672B2 (en) 2016-11-29
HK1203956A1 (en) 2015-11-06
WO2014005098A3 (en) 2014-02-27
NZ628880A (en) 2016-08-26

Similar Documents

Publication Publication Date Title
EP2751060A4 (en) Process for producing both biobased succinic acid and 2,5-furandicarboxylic acid
EA033455B1 (en) Crystalline forms of substituted 5-fluoro-1h-pyrazolopyridines, processes for preparing same, use thereof for producing a medicament, medicament and method of treatment based thereof
PL2630108T3 (en) Process for the preparation of 2,3,3,3 tetrafluoropropene
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
IL230635A (en) 1,2,3,4-tetrahydroquinoline derivative useful for the treatment of diabetes
IL216935A0 (en) Process for the preparation of nacre mechano-structured by mechanosynthesis, mechano-structured nacre thus obtained and uses thereof
FR2962731B1 (en) PROCESS FOR THE PREPARATION OF AMINO-BENZOYL-BENZOFURAN DERIVATIVES
WO2014072961A3 (en) Polymorphic forms of suvoroxant
ZA201404440B (en) Process for the preparation of travoprost
IN2014DN10680A (en)
MX2014010433A (en) Novel crystalline form of sitagliptin sulfate.
WO2015068175A3 (en) An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
HK1199242A1 (en) Process for the production of 1,3-butadiene 13-
EA201300647A1 (en) OPTIMIZED SYNTHESIS OF PURE NONPOLYMORPHIC CRYSTALLINE YELLOW ACIDS WITH A PARTICLE SIZE
WO2010079045A3 (en) Crystalline salt forms of flibanserine
WO2015052568A3 (en) Solid forms of curcumin and derivatives thereof
HK1223334A1 (en) Process for the manufacture of implants or intermediate products of such implants as well as implants and intermediate products obtained by such process
WO2011100282A3 (en) Imatinib mesylate polymorphs
WO2014178064A3 (en) "an improved process for the preparation of fluvoxamine maleate"
SG11201405376TA (en) CRYSTALLINE FORMS OF 5α-ANDROSTANE-3β, 5, 6β-TRIOL AND PREPARATION METHODS THEREOF
HK1206729A1 (en) [3-heteroaryl-2-trifluoromethyl-propyl]-piperidin-1-yle or - morpholin-4-yle compounds as trpa1 antagonists for the treatment of respiratory diseases trpa1 [3--2--]- -1---4-
WO2013114397A3 (en) Pharmaceutically acceptable salt of brinzolamide and composition thereof
HK1199884A1 (en) Method for producing cereulide and derivative thereof, intermediate for production of cereulide, and cereulide derivative cereulide cereulide cereulide
WO2014102820A3 (en) Rivaroxaban intermediate and preparation thereof
IL229669A0 (en) Process for preparation of 1,2,3 -triazole-4-carboxamides